Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 24.99M | 9.73M | 17.90M | Gross Profit |
0.00 | -6.10M | 19.98M | 9.73M | 17.90M | EBIT |
-127.61M | -152.04M | -72.55M | -61.43M | -39.19M | EBITDA |
-127.61M | -136.53M | -64.70M | -60.41M | -37.41M | Net Income Common Stockholders |
-117.12M | -142.66M | -67.03M | -62.00M | -36.68M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
176.30M | 159.71M | 257.66M | 277.54M | 94.61M | Total Assets |
220.22M | 207.29M | 330.69M | 338.94M | 153.84M | Total Debt |
17.23M | 20.92M | 21.02M | 20.94M | 21.64M | Net Debt |
-39.26M | -138.79M | -236.63M | -256.60M | -62.69M | Total Liabilities |
33.61M | 37.12M | 38.35M | 35.81M | 44.01M | Stockholders Equity |
186.61M | 170.18M | -238.11M | -168.32M | -106.33M |
Cash Flow | Free Cash Flow | |||
-93.50M | -98.18M | -61.55M | -64.10M | -42.54M | Operating Cash Flow |
-92.38M | -93.72M | -44.77M | -51.05M | -41.55M | Investing Cash Flow |
-119.24M | -4.46M | -16.78M | -2.80M | 115.22M | Financing Cash Flow |
111.31M | 236.00K | 41.51M | 242.69M | 303.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
64 Neutral | $58.96M | 1.86 | -58.97% | ― | 36.45% | ― | |
56 Neutral | $55.76M | 3.00 | 19.05% | ― | 40.98% | ― | |
51 Neutral | $5.20B | 3.26 | -40.34% | 2.93% | 17.68% | 1.94% | |
40 Underperform | $47.91M | ― | -33.30% | ― | -100.00% | 37.59% | |
40 Underperform | $63.64M | ― | -54.07% | ― | ― | 10.84% | |
37 Underperform | $42.49M | ― | -295.35% | ― | 184.12% | 31.92% | |
27 Underperform | $48.10M | ― | -65.65% | ― | ― | 59.75% |
On April 17, 2025, Adicet Bio announced the appointment of Michael Grissinger to its Board of Directors. Grissinger, with over four decades of experience in pharmaceutical business development and strategic transactions, is expected to bring valuable insights to Adicet as it advances its gamma delta T cell platform. His extensive background, particularly in immunology, will be instrumental in guiding the company’s growth and development of therapies for autoimmune and solid tumor indications.
Spark’s Take on ACET Stock
According to Spark, TipRanks’ AI Analyst, ACET is a Underperform.
Adicet Bio faces significant financial challenges with no revenue and consistent losses, presenting major risk factors. The technical analysis suggests a bearish trend, while poor valuation due to a negative P/E ratio further impacts the stock’s attractiveness. Without improvement in revenue and cash flow management, the outlook remains concerning.
To see Spark’s full report on ACET stock, click here.